Compare Ishares Msci Brazil ETF (EWZ) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Natera Inc. Common Stock — how do they compare? Ishares Msci Brazil ETF trades at $41.99 (market cap $13.28B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 4.3× Ishares Msci Brazil ETF's market cap, and Ishares Msci Brazil ETF is more actively traded (59,308,012 versus 1,131,157). Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Natera Inc. Common Stock for 0 Days on average.
| EWZ | NTRA | |
|---|---|---|
Market Cap | $13.28B | $57.03B |
Volume | 59,308,012 | 1,131,157 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.54 | $425.64 |
52-Week Low | $29.24 | $179.42 |
Typical Hold Time | 50 Days | 0 Days |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, trades at $42.87, down 1.54% today, with a bullish technical signal driven by moving averages but showing overbought RSI levels. The ETF is attracting significant attention due to Brazil's upcoming October election, with institutional investors accumulating positions through call options. Recent news highlights EWZ as a diversification tool against U.S. tech concentration and potential beneficiary of Brazilian economic policies.
The outlook for EWZ hinges on Brazil's political election outcome and commodity trends, offering asymmetric upside but facing currency and political volatility risks. Wall Street positioning suggests optimism, though investors must weigh the ETF's higher expense ratio against alternatives like FLBR for Brazilian exposure.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
